Novo Integrated Sciences Inc 的盈利品質評分為 B+/55.62316。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Novo Integrated Sciences Inc 何時發布財報?
Novo Integrated Sciences Inc 的下一份財報預計在 2026-03-16 發布
Novo Integrated Sciences Inc 的預期收益是多少?
根據華爾街分析師的預測,Novo Integrated Sciences Inc 的預期收益為 $
Novo Integrated Sciences Inc 是否超出收益預期?
Novo Integrated Sciences Inc 最近的收益為 $, 預期。
關鍵數據
前收市價
$0.0006
開盤價
$0.005
當日範圍
$0.0031 - $0.005
52週區間
$0.0001 - $0.06
交易量
1.5K
平均成交量
3.4K
股息收益率
--
每股盈餘 (TTM)
-0.91
市值
$61.1K
什麼是 NVOS?
Novo Integrated Sciences, Inc. engages in the provision of medical services. The company is headquartered in Bellevue, Washington and currently employs 115 full-time employees. The company went IPO on 2005-07-12. The company operates through two reportable segments: healthcare services and product sales. Its businesses include healthcare, medical technology, manufacturing, research and diagnostics, and products and brands. Its specialized primary health care services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, and others. Its products include Terragenx and ProDip (dietary supplement pouches). Terragenx is a micro-dosing IoNovo Iodine product for all ages and lifestyles. Its medical technologies include telemedicine, and remote patient monitoring.